Evidence map›Paper›PMID 42604891›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [

Ya Liu, Tingting Xu, Hongyu Yang, Zhanwen Huang, Haoyuan Ding, Yu Zhang, Yue Chen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ya Liu *Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
Tingting Xu *Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
Hongyu Yang *Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
Zhanwen HuangDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China.
Haoyuan DingDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. 315699969@qq.com.
Yu ZhangDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. zhangyu309@126.com.
Yue ChenDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, PR China. chenyue5523@126.com.ORCID http://orcid.org/0000-0003-4088-7649

Funding

the Gansu Provincial Science and Technology Major Project 23ZDFA014the National Key Research and Development Program (NKRDP) Project 2024YFC2419405the Scientific Research Project of Southwest Medical University 2023QN093
6 · The paper itself

Abstract

purposeTo investigate the association between baseline NETPET score and prognosis in patients with neuroendocrine tumors (NETs) receiving [

methodsThis retrospective study included patients with NETs treated with [

resultsForty-eight patients were enrolled (P1: n = 14, P2-4: n = 22, P5: n = 12). The P1 group achieved significantly better PFS than the P2-4 and P5 groups (2-year PFS rates: 0.83 vs. 0.32 vs. 0.10; log-rank P < 0.0001). Univariate analysis revealed a significant association of NETPET score with PFS (P2-4 vs. P1: HR = 7.07, P = 0.009; P5 vs. P1: HR = 17.0, P < 0.001). Multivariate analysis demonstrated the NETPET score to be independently associated with PFS (P2-4 vs. P1: P = 0.003; P5 vs. P1: P < 0.001). Its predictive value for overall survival was limited (P > 0.05).

conclusionThe NETPET score was independently associated with progression-free survival and may serve as a potential imaging biomarker for pretreatment risk stratification in NET patients receiving [

Indexed as

[225Ac]Ac-DOTATATEBiomarkerNETPETNeuroendocrine tumors

Identifiers

PMID42604891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.